WHO Model List of Essential Medicines for Children

4th list

(April 2013)

Status of this document

This is a reprint of the text on the WHO Medicines web site

http://www.who.int/medicines/publications/essentialmedicines/en/index.html



WHO Model List of Essential Medicines for Children

Explanatory Notes

This Model List is intended for use for children up to 12 years of age.

The **core list** presents a list of minimum medicine needs for a basic health-care system, listing the most efficacious, safe and cost-effective medicines for priority conditions. Priority conditions are selected on the basis of current and estimated future public health relevance, and potential for safe and cost-effective treatment.

The **complementary list** presents essential medicines for priority diseases, for which specialized diagnostic or monitoring facilities, and/or specialist medical care, and/or specialist training are needed. In case of doubt medicines may also be listed as complementary on the basis of consistent higher costs or less attractive cost-effectiveness in a variety of settings.

The **square box symbol** (\square) is primarily intended to indicate similar clinical performance within a pharmacological class. The listed medicine should be the example of the class for which there is the best evidence for effectiveness and safety. In some cases, this may be the first medicine that is licensed for marketing; in other instances, subsequently licensed compounds may be safer or more effective. Where there is no difference in terms of efficacy and safety data, the listed medicine should be the one that is generally available at the lowest price, based on international drug price information sources.

Therapeutic equivalence is only indicated on the basis of reviews of efficacy and safety and when consistent with WHO clinical guidelines. National lists should not use a similar symbol and should be specific in their final selection, which would depend on local availability and price.

The format and numbering of the 18th WHO Model List of Essential Medicines have been retained but, as indicated in the text, some sections have been deleted because they contain medicines that are not relevant for children.

a indicates that there is an age or weight restriction on use of the medicines; the details for each medicine are in Table 1.

In the List of Essential Medicines for Children, an additional symbol is used:

R indicates that the Committee has endorsed the medicine as essential but has requested a review of the efficacy and safety to confirm this decision, or to expand use to additional age groups.

The presence of an entry on the Essential Medicines List carries no assurance as to pharmaceutical quality. It is the responsibility of the relevant national or regional drug regulatory authority to ensure that each product is of appropriate pharmaceutical quality (including stability) and that when relevant, different products are interchangeable.

For recommendations and advice concerning all aspects of the quality assurance of medicines see the WHO Medicines web site http://www.who.int/medicines/areas/quality assurance/en/index.html

Medicines and dosage forms are listed in alphabetical order within each section and there is no implication of preference for one form over another. Standard treatment guidelines should be consulted for information on appropriate dosage forms.

The main terms used for dosage forms in the Essential Medicines List can be found in Annex 1. Definitions of many of these terms and pharmaceutical quality requirements applicable to the different categories are published in the current edition of *The International Pharmacopoeia* http://www.who.int/medicines/publications/pharmacopoeia/en/index.html.

1. ANAESTHETICS	
1.1 General anaesthetics and oxyg	gen
1.1.1 Inhalational medicines	
halothane	Inhalation.
isoflurane	Inhalation.
nitrous oxide	Inhalation.
oxygen	Inhalation (medicinal gas).
1.1.2 Injectable medicines	
ketamine	Injection: 50 mg (as hydrochloride)/ml in 10-ml vial.
	Injection: 10 mg/ml; 20 mg/ml.
propofol*	* Thiopental may be used as an alternative depending on local availability and cost.
1.2 Local anaesthetics	
	Injection: 0.25%; 0.5% (hydrochloride) in vial.
□ bupivacaine	Injection for spinal anaesthesia: 0.5% (hydrochloride) in 4-ml ampoule to be mixed with 7.5% glucose solution.
	Injection: 1%; 2% (hydrochloride) in vial.
□ lidocaine	Injection for spinal anaesthesia: 5% (hydrochloride) in 2-ml ampoule to be mixed with 7.5% glucose solution.
	Topical forms: 2% to 4% (hydrochloride).
	Dental cartridge: 2% (hydrochloride) + epinephrine 1:80 000.
lidocaine + epinephrine (adrenaline)	Injection: 1%; 2% (hydrochloride or sulfate) + epinephrine 1:200 000 in vial.
1.3 Preoperative medication and	sedation for short-term procedures
atropine	Injection: 1 mg (sulfate) in 1-ml ampoule.
	Injection: 1 mg/ml.
□ midazolam	Oral liquid: 2 mg/ml.
	Tablet: 7.5 mg; 15 mg.
morphine	Injection: 10 mg (sulfate or hydrochloride) in 1-ml ampoule.
2. MEDICINES FOR PAIN AND	PALLIATIVE CARE
2.1 Non-opioids and non-steroida	l anti-inflammatory medicines (NSAIMs)
	Oral liquid: 200 mg/5 ml.
ibuprofen a	Tablet: 200 mg; 400 mg; 600 mg.
	a Not in children less than 3 months.

	Oral liquid: 125 mg/5 ml.
paracetamol*	Suppository: 100 mg.
	Tablet: 100 mg to 500 mg.
	* Not recommended for anti-inflammatory use due to lack of proven benefit to that effect.
2.2 Opioid analgesics	
	Granules (slow release; to mix with water): 20 mg to 200 mg (morphine sulfate).
	Injection: 10 mg (morphine hydrochloride or morphine sulfate) in 1-ml ampoule.
morphine*	Oral liquid: 10 mg (morphine hydrochloride or morphine sulfate)/5 ml.
	Tablet (immediate release): 10 mg (morphine sulfate).
	Tablet (slow release): 10 mg to 200 mg (morphine hydrochloride or morphine sulfate).
	* Alternatives limited to hydromorphone and oxycodone.
2.3 Medicines for other symptoms	common in palliative care
amitriptyline	Tablet: 10 mg; 25 mg.
	Injection: 50 mg/ml.
cyclizine	Tablet: 50 mg.
	Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt).
dexamethasone	Oral liquid: 2 mg/5 ml.
	Tablet: 2 mg.
	Injection: 5 mg/ml.
diagrapam	Oral liquid: 2 mg/5 ml.
diazepam	Rectal solution: 2.5 mg; 5 mg; 10 mg.
	Tablet: 5 mg; 10 mg.
docusate sodium	Capsule: 100 mg.
docusate soutuin	Oral liquid: 50 mg/5 ml.
fluoxetine a	Solid oral dosage form: 20 mg (as hydrochloride).
masseume 🖭	a >8 years.
hyoscine hydrobromide	Injection: 400 micrograms/ml; 600 micrograms/ml.
11, oceane il garooronide	Transdermal patches: 1 mg/72 hours.
lactulose	Oral liquid: 3.1-3.7 g/5 ml.
	Injection: 1 mg/ml; 5 mg/ml.
midazolam	Oral liquid: 2 mg/ml. Oral value of the second of the sec

	Injection: 2 mg base/ml in 2-ml ampoule (as hydrochloride).
ondansetron a	Oral liquid: 4 mg base/5 ml.
	Solid oral dosage form: Eq 4 mg base; Eq 8 mg base.
	a >1 month.
senna	Oral liquid: 7.5 mg/5 ml.
3. ANTIALLERGICS AND ME	DICINES USED IN ANAPHYLAXIS
dexamethasone	Injection: 4 mg/ml in 1-ml ampoule (as disodium phosphate salt).
epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule.
hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial.
	Oral liquid: 1 mg/ml.
□ loratadine*	Tablet: 10 mg.
	* There maybe a role for sedating antihistamines for limited indications.
- 1:1	Oral liquid: 5 mg/ml.
□ prednisolone	Tablet: 5 mg; 25 mg.
4. ANTIDOTES AND OTHER	SUBSTANCES USED IN POISONINGS
4.1 Non-specific	
charcoal, activated	Powder.
4.2 Specific	
	Injection: 200 mg/ml in 10-ml ampoule.
acetylcysteine	Oral liquid: 10%; 20%.
atropine	Injection: 1 mg (sulfate) in 1-ml ampoule.
calcium gluconate	Injection: 100 mg/ml in 10-ml ampoule.
naloxone	Injection: 400 micrograms (hydrochloride) in 1-ml ampoule.
Complementary List	
deferoxamine	Powder for injection: 500 mg (mesilate) in vial.
dimercaprol	Injection in oil: 50 mg/ml in 2-ml ampoule.
fomepizole	Injection: 5 mg/ml (sulfate) in 20-ml ampoule or 1 g/ml (base) in 1.5-ml ampoule.
sodium calcium edetate	Injection: 200 mg/ml in 5-ml ampoule.
succimer	Solid oral dosage form: 100 mg.
5. ANTICONVULSANTS/ANT	 TIEPILEPTICS
	Oral liquid: 100 mg/5 ml.
carbamazepine	Tablet (chewable): 100 mg; 200 mg.
	Tablet (scored): 100 mg; 200 mg.

diazepam	Gel or rectal solution: 5 mg/ml in 0.5 ml; 2-ml; 4-ml tubes.	
□ lorazepam	Parenteral formulation: 2 mg/ml in 1-ml ampoule; 4 mg/ml in 1-ml ampoule.	
phenobarbital	Injection: 200 mg/ml (sodium).	
	Oral liquid: 15 mg/5 ml.	
	Tablet: 15 mg to 100 mg.	
	Injection: 50 mg/ml in 5-ml vial (sodium salt).	
	Oral liquid: 25 mg to 30 mg/5 ml.*	
	Solid oral dosage form: 25 mg; 50 mg; 100 mg (sodium salt).	
phenytoin	Tablet (chewable): 50 mg.	
	* The presence of both 25 mg/5 ml and 30 mg/5 ml strengths on the same market would cause confusion in prescribing and dispensing and should be avoided.	
	Oral liquid: 200 mg/5 ml.	
valproic acid (sodium valproate)	Tablet (crushable): 100 mg.	
	Tablet (enteric-coated): 200 mg; 500 mg (sodium valproate).	
Complementary List		
ethosuximide	Capsule: 250 mg.	
emosuximiue	Oral liquid: 250 mg/5 ml.	
6. ANTI-INFECTIVE MEDICINE	S	
6.1 Anthelminthics		
6.1.1 Intestinal anthelminthics		
albendazole	Tablet (chewable): 400 mg.	
levamisole	Tablet: 50 mg; 150 mg (as hydrochloride).	
mebendazole	Tablet (chewable): 100 mg; 500 mg.	
niclosamide	Tablet (chewable): 500 mg.	
praziquantel	Tablet: 150 mg; 600 mg.	
nymental	Oral liquid: 50 mg (as embonate or pamoate)/ml.	
pyrantel	Tablet (chewable): 250 mg (as embonate or pamoate).	
6.1.2 Antifilarials		
albendazole	Tablet (chewable): 400 mg.	
diethylcarbamazine	Tablet: 50 mg; 100 mg (dihydrogen citrate).	
ivermectin	Tablet (scored): 3 mg.	
6.1.3 Antischistosomals and othe	r antitrematode medicines	
praziquantel	Tablet: 600 mg.	
triclabendazole	Tablet: 250 mg.	

Complementary List	
	Capsule: 250 mg.
oxamniquine*	Oral liquid: 250 mg/5 ml.
	* Oxamniquine is listed for use when praziquantel treatment fails.
6.2 Antibacterials	
6.2.1 Beta Lactam medicines	5
amoxicillin	Powder for oral liquid: 125 mg (as trihydrate)/5 ml; 250 mg (as trihydrate)/5 ml.
	Solid oral dosage form: 250 mg; 500 mg (as trihydrate).
amoxicillin + clavulanic acid	Oral liquid: 125 mg amoxicillin + 31.25 mg clavulanic acid/5 ml AND 250 mg amoxicillin + 62.5 mg clavulanic acid/5 ml.
	Tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt).
ampicillin	Powder for injection: 500 mg; 1 g (as sodium salt) in vial.
benzathine benzylpenicillin	Powder for injection: 900 mg benzylpenicillin (= 1.2 million IU) in 5-ml vial; 1.44 g benzylpenicillin (= 2.4 million IU) in 5-ml vial.
benzylpenicillin	Powder for injection: 600 mg (= 1 million IU); 3 g (= 5 million IU) (sodium or potassium salt) in vial.
cefalexin	Powder for reconstitution with water: 125 mg/5 ml; 250 mg/5 ml (anhydrous).
	Solid oral dosage form: 250 mg (as monohydrate).
	Powder for injection: 1 g (as sodium salt) in vial.
□ cefazolin* a	* For surgical prophylaxis.
	a >1 month.
	Powder for injection: 250 mg; 1 g (as sodium salt) in vial.
ceftriaxone* a	* Do not administer with calcium and avoid in infants with hyperbilirubinemia.
	a >41 weeks corrected gestational age.
	Capsule: 500 mg; 1 g (as sodium salt).
□ cloxacillin	Powder for injection: 500 mg (as sodium salt) in vial.
	Powder for oral liquid: 125 mg (as sodium salt)/5 ml.
1 4 1 1 111	Powder for oral liquid: 250 mg (as potassium salt)/5 ml.
phenoxymethylpenicillin	Tablet: 250 mg (as potassium salt).
procaine benzylpenicillin*	Powder for injection: 1 g (=1 million IU); 3 g (=3 million IU) ir vial.
	* Procaine benzylpenicillin is not recommended as first-line treatment for neonatal sepsis except in settings with high neonatal mortality, when given by trained health workers in cases where hospital care is not achievable.

Complementary List	
	Powder for injection: 250 mg per vial (as sodium salt).
cefotaxime*	* 3rd generation cephalosporin of choice for use in hospitalized neonates.
ceftazidime	Powder for injection: 250 mg or 1 g (as pentahydrate) in vial.
	Powder for injection: 250 mg (as monohydrate) + 250 mg (as sodium salt); 500 mg (as monohydrate) + 500 mg (as sodium salt) in vial.
imipenem* + cilastatin*	* Only listed for the treatment of life-threatening hospital-based infection due to suspected or proven multidrug-resistant infection. Meropenem is indicated for the treatment of meningitis and is licensed for use in children over the age of 3 months.
6.2.2 Other antibacterials	
	Capsule: 250 mg; 500 mg (anhydrous).
azithromycin*	Oral liquid: 200 mg/5 ml.
	* Only listed for trachoma.
	Capsule: 250 mg.
	Oily suspension for injection*: 0.5 g (as sodium succinate)/ml in 2-ml ampoule.
chloramphenicol	* Only for the presumptive treatment of epidemic meningitis in children older than 2 years.
	Oral liquid: 150 mg (as palmitate)/5 ml.
	Powder for injection: 1 g (sodium succinate) in vial.
	Oral liquid: 250 mg/5 ml (anhydrous).
ciprofloxacin	Solution for IV infusion: 2 mg/ml (as hyclate).
	Tablet: 250 mg (as hydrochloride).
	Oral liquid: 25 mg/5 ml; 50 mg/5 ml (anhydrous).
doxycycline a	Solid oral dosage form: 50 mg; 100 mg (as hyclate).
doxycycline <u>B</u>	Use in children <8 years only for life-threatening infections when no alternative exists.
erythromycin	Powder for oral liquid: 125 mg/5 ml (as stearate or estolate or ethyl succinate).
	Solid oral dosage form: 250 mg (as stearate or estolate or ethyl succinate).
□ gentamicin	Injection: 10 mg; 40 mg (as sulfate)/ml in 2-ml vial.
metronidazole	Injection: 500 mg in 100-ml vial.
	Oral liquid: 200 mg (as benzoate)/5 ml.
	Tablet: 200 mg to 500 mg.
with Computation	Oral liquid: 25 mg/5 ml.
nitrofurantoin	Tablet: 100 mg.

	Injection:
	80 mg + 16 mg/ml in 5-ml ampoule;
sulfamethoxazole + trimethoprim	80 mg + 16 mg/ml in 10-ml ampoule.
	Oral liquid: 200 mg + 40 mg/5 ml.
	Tablet: 100 mg + 20 mg; 400 mg + 80 mg.
trimethoprim a	Oral liquid: 50 mg/5 ml.
	Tablet: 100 mg; 200 mg.
	a >6 months.
Complementary List	
clindamycin	Capsule: 150 mg (as hydrochloride).
	Injection: 150 mg (as phosphate)/ml.
	Oral liquid: 75 mg/5 ml (as palmitate).
vancomycin	Powder for injection: 250 mg (as hydrochloride) in vial.

6.2.3 Antileprosy medicines

Medicines used in the treatment of leprosy should never be used except in combination. Combination therapy is essential to prevent the emergence of drug resistance. Colour coded blister packs (MDT blister packs) containing standard two medicine (paucibacillary leprosy) or three medicine (multibacillary leprosy) combinations for adult and childhood leprosy should be used. MDT blister packs can be supplied free of charge through WHO.

clofazimine	Capsule: 50 mg; 100 mg.
dapsone	Tablet: 25 mg; 50 mg; 100 mg.
rifampicin	Solid oral dosage form: 150 mg; 300 mg.

6.2.4 Antituberculosis medicines

WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

ethambutol	Oral liquid: 25 mg/ml.
	Tablet: 100 mg; 400 mg (hydrochloride).
isoniazid	Oral liquid: 50 mg/5 ml.
	Tablet: 100 mg to 300 mg.
	Tablet (scored): 50 mg.
pyrazinamide	Oral liquid: 30 mg/ml.
	Tablet: 400 mg.
	Tablet (dispersible): 150 mg.
	Tablet (scored): 150 mg.
rifampicin	Oral liquid: 20 mg/ml.
	Solid oral dosage form: 150 mg; 300 mg.

Complementary List	
ļ	reatment of multidrug-resistant tuberculosis (MDR-TB) should ring to WHO standards for TB control.
amikacin	Powder for injection: 100 mg; 500 mg; 1 g (as sulfate) in vial.
capreomycin	Powder for injection: 1 g (as sulfate) in vial.
cycloserine	Solid oral dosage form: 250 mg.
ethionamide*	Tablet: 125 mg; 250 mg.
einionumiue	* Prothionamide may be an alternative.
kanamycin	Powder for injection: 1 g (as sulfate) in vial.
	Tablet: 250 mg; 500 mg.
levofloxacin*	* Ofloxacin and moxifloxacin may be alternatives based on availability and programme considerations.
n aminocaliondia acid	Granules: 4 g in sachet.
p-aminosalicylic acid	Tablet: 500 mg.
streptomycin	Powder for injection: 1 g (as sulfate) in vial.
6.3 Antifungal medicines	
amphotericin B	Powder for injection: 50 mg in vial (as sodium deoxycholate or liposomal complex).
	Capsule: 50 mg.
□ fluconazole	Injection: 2 mg/ml in vial.
	Oral liquid: 50 mg/5 ml.
flucytosine	Capsule: 250 mg.
nucytosnie	Infusion: 2.5 g in 250 ml.
grisoofulvin	Oral liquid: 125 mg/5 ml.
griseofulvin	Solid oral dosage form: 125 mg; 250 mg.
nystatin	Lozenge: 100 000 IU.
	Oral liquid: 50 mg/5 ml; 100 000 IU/ml.
	Tablet: 100 000 IU; 500 000 IU.
Complementary List	
potassium iodide	Saturated solution.
6.4 Antiviral medicines	
6.4.1 Antiherpes medicines	
	Oral liquid: 200 mg/5 ml.
aciclovir	Powder for injection: 250 mg (as sodium salt) in vial.
	Tablet: 200 mg.

6.4.2 Antiretrovirals

Based on current evidence and experience of use, medicines in the following three classes of antiretrovirals are included as essential medicines for treatment and prevention of HIV (prevention of mother-to-child transmission and post-exposure prophylaxis). WHO emphasizes the importance of using these products in accordance with global and national guidelines. WHO recommends and endorses the use of fixed-dose combinations and the development of appropriate new fixed-dose combinations, including modified dosage forms, non-refrigerated products and paediatric dosage forms of assured pharmaceutical quality.

Scored tablets can be used in children and therefore can be considered for inclusion in the listing of tablets, provided adequate quality products are available.

6.4.2.1 Nucleoside/Nucleotide	reverse	transcrintase	inhibitors
U.T.Z. I IVACICOSIAC/ IVACICOLIAC	1000130	ti ai isci iptasc	11 11 11 11 11 11 11 11 11

abacavir (ABC)	Oral liquid: 100 mg (as sulfate)/5 ml.
abacavii (ADC)	Tablet: 300 mg (as sulfate).
	Buffered powder for oral liquid: 100 mg; 167 mg; 250 mg-packets.
didanosine (ddI)	Capsule (unbuffered enteric-coated): 125 mg; 200 mg; 250 mg; 400 mg.
	Tablet (buffered chewable, dispersible): 25 mg; 50 mg; 100 mg; 150 mg; 200 mg.
	Capsule: 200 mg.
	Oral liquid: 10 mg/ml.
emtricitabine (FTC)* a	* FTC is an acceptable alternative to 3TC, based on knowledge of the pharmacology, the resistance patterns and clinical trials of antiretrovirals.
	a >3 months.
1 1: (OTC)	Oral liquid: 50 mg/5 ml.
lamivudine (3TC)	Tablet: 150 mg.
stavudine (d4T)	Capsule: 15 mg; 20 mg; 30 mg.
	Powder for oral liquid: 5 mg/5 ml.
zidovudine (ZDV or AZT)	Capsule: 100 mg; 250 mg.
	Oral liquid: 50 mg/5 ml.
	Solution for IV infusion injection: 10 mg/ml in 20-ml vial.
	Tablet: 300 mg.
6 1 2 2 Non-nucleoside reve	arsa transcrintasa inhihitars

6.4.2.2 Non-nucleoside reverse transcriptase inhibitors

efavirenz (EFV or EFZ) a	Capsule: 50 mg; 100 mg; 200 mg.
	Oral liquid: 150 mg/5 ml.
	Tablet: 600 mg.
	a >3 years or >10 kg.
nevirapine (NVP)	Oral liquid: 50 mg/5 ml.
	Tablet: 200 mg.

6.4.2.3 Protease inhibitors

Selection of protease inhibitor(s) from the Model List will need to be determined by each country after consideration of international and national treatment guidelines and experience. Ritonavir is recommended for use in combination as a pharmacological booster, and not as an antiretroviral in its own right. All other protease inhibitors should be used in boosted forms (e.g. with ritonavir).

right. All other protease inhibitors should be used in boosted forms (e.g. with ritonavir).		
atazanavir a	Solid oral dosage form: 100 mg; 150 mg; 300 mg (as sulfate).	
	a >25 kg.	
	Capsule: 133.3 mg + 33.3 mg.	
lopinavir + ritonavir (LPV/r)	Oral liquid: 400 mg + 100 mg/5 ml.	
	Tablet (heat stable): 100 mg + 25 mg; 200 mg + 50 mg.	
	Oral liquid: 400 mg/5 ml.	
ritonavir	Solid oral dosage form: 100 mg.	
	Tablet (heat stable): 25 mg; 100 mg.	
saquinavir (SQV) a	Solid oral dosage form: 200 mg (as mesilate).	
	a >25 kg.	
FIXED-DOSE COMBINATIONS		
	Tablet: 150 mg + 200 mg + 30 mg.	
lamivudine + nevirapine + stavudine	Tablet (dispersible):	
	30 mg + 50 mg + 6 mg; 60 mg + 100 mg + 12 mg.	
lamivudine + nevirapine + zidovudine	Tablet: 30 mg + 50 mg + 60 mg; 150 mg + 200 mg + 300 mg.	

lamivudine + zidovudine 6.4.3 Other antivirals

	Capsule: 30 mg; 45 mg; 75 mg (as phosphate).
oseltamivir* * Potentially sever suspected influen	Oral powder: 12 mg/ml.
	* Potentially severe or complicated illness due to confirmed or suspected influenza virus infection in accordance with WHO Treatment Guidelines.
	Injection for intravenous administration: 800 mg and 1 g in 10-ml phosphate buffer solution.
ribavirin*	Solid oral dosage form: 200 mg; 400 mg; 600 mg.
	* For the treatment of viral haemorrhagic fevers only.

Tablet: 30 mg + 60 mg; 150 mg + 300 mg.

6.5 Antiprotozoal medicines

6.5.1 Antiamoebic and antigiardiasis medicines

	Tablet: 500 mg (furoate).
diloxanide a	a >25 kg.
	Injection: 500 mg in 100-ml vial.
□ metronidazole	Oral liquid: 200 mg (as benzoate)/5 ml.
	Tablet: 200 mg to 500 mg.

6.5.2 Antileishmaniasis medicines		
amphotericin B	Powder for injection: 50 mg in vial. As sodium deoxycholate or liposomal complex.	
miltefosine	Solid oral dosage form: 10 mg; 50 mg.	
paromomycin	Solution for intramuscular injection: 750 mg of paromomycin base (as the sulfate).	
sodium stibogluconate or meglumine antimoniate	Injection: 100 mg/ml, 1 vial = 30 ml or 30%, equivalent to approximately 8.1% antimony (pentavalent) in 5-ml ampoule.	

6.5.3 Antimalarial medicines

6.5.3.1 For curative treatment

Medicines for the treatment of *P. falciparum* malaria cases should be used in combination. The list currently recommends combinations according to treatment guidelines. WHO recognizes that not all of the FDCs in the WHO Treatment Guidelines exist, and encourages their development and rigorous testing. WHO also encourages development and testing of rectal dosage formulations.

0 1		
amodiaquine*	Tablet: 153 mg or 200 mg (as hydrochloride).	
amoulaquine	* To be used in combination with artesunate 50 mg.	
artemether*	Oily injection: 80 mg/ml in 1-ml ampoule.	
	* For use in the management of severe malaria.	
	Tablet: 20 mg + 120 mg.	
artemether + lumefantrine*	Tablet (dispersible): 20 mg + 120 mg.	
arement's functional for	* Not recommended in the first trimester of pregnancy or in children below 5 kg.	
	Injection: ampoules, containing 60 mg anhydrous artesunic acid with a separate ampoule of 5% sodium bicarbonate solution.	
	For use in the management of severe malaria.	
artesunate*	Rectal dosage form: 50 mg; 200 mg capsules (for pre-referral treatment of severe malaria only; patients should be taken to an appropriate health facility for follow-up care).	
	Tablet: 50 mg.	
	* To be used in combination with either amodiaquine, mefloquine or sulfadoxine + pyrimethamine.	
	Tablet: 25 mg + 67.5 mg; 50 mg + 135 mg; 100 mg + 270 mg.	
artesunate + amodiaquine*	* Other combinations that deliver the target doses required such as 153 mg or 200 mg (as hydrochloride) with 50 mg artesunate can be alternatives.	
artesunate + mefloquine	Tablet: 25 mg + 55 mg; 100 mg + 220 mg.	
	Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.	
chloroquine*	Tablet: 100 mg; 150 mg (as phosphate or sulfate).	
	* For use only for the treatment of <i>P.vivax</i> infection.	

	Capsule: 100 mg (as hydrochloride or hyclate).	
doxycycline*	Tablet (dispersible): 100 mg (as monohydrate).	
	* For use only in combination with quinine.	
	Tablet: 250 mg (as hydrochloride).	
mefloquine*	* To be used in combination with artesunate 50 mg.	
	Tablet: 7.5 mg; 15 mg (as diphosphate).	
primaquine*	* Only for use to achieve radical cure of <i>P.vivax</i> and <i>P.ovale</i> infections, given for 14 days.	
	Injection: 300 mg quinine hydrochloride/ml in 2-ml ampoule.	
quinine*	Tablet: 300 mg (quinine sulfate) or 300 mg (quinine bisulfate).	
quinine*	* For use only in the management of severe malaria, and should be used in combination with doxycycline.	
16.1	Tablet: 500 mg + 25 mg.	
sulfadoxine + pyrimethamine*	* Only in combination with artesunate 50 mg.	
6.5.3.2 For prophylaxis		
	Oral liquid: 50 mg (as phosphate or sulfate)/5 ml.	
chloroquine*	Tablet: 150 mg (as phosphate or sulfate).	
	* For use only for the treatment of <i>P.vivax</i> infection.	
1	Solid oral dosage form: 100 mg (as hydrochloride or hyclate).	
doxycycline a	a >8 years.	
mefloquine a	Tablet: 250 mg (as hydrochloride).	
menoquine a	a >5 kg or >3 months.	
proguanil*	Tablet: 100 mg (as hydrochloride).	
proguaini	* For use only in combination with chloroquine.	
6.5.4 Antipneumocystosis and a	antitoxoplasmosis medicines	
pyrimethamine	Tablet: 25 mg.	
sulfadiazine	Tablet: 500 mg.	
	Injection:	
sulfamethoxazole + trimethoprim	80 mg + 16 mg/ml in 5-ml ampoule; 80 mg + 16 mg/ml in 10-ml ampoule.	
1	Oral liquid: 200 mg + 40 mg/5 ml.	
	Tablet: 100 mg + 20 mg; 400 mg + 80 mg.	
6.5.5 Antitrypanosomal medicir	nes	
6.5.5.1 African trypanosomiasis	•	
Medicines for the treatment of 1st stage	African trypanosomiasis	
	Powder for injection: 200 mg (as isetionate) in vial.	
pentamidine*	* To be used for the treatment of <i>Trypanosoma brucei gambiense</i> infection.	

	Powder for injection: 1 g in vial.	
suramin sodium*	* To be used for the treatment of the initial phase of	
	Trypanosoma brucei rhodesiense infection.	
Medicines for the treatment of 2nd sta	ge African trypanosomiasis	
	Injection: 200 mg (hydrochloride)/ml in 100-ml bottle.	
eflornithine*	* To be used for the treatment of <i>Trypanosoma brucei gambiense</i> infection.	
	Tablet: 120 mg.	
nifurtimox*	* Only to be used in combination with eflornithine, for the treatment of <i>Trypanosoma brucei gambiense</i> infection.	
Complementary List		
melarsoprol	Injection: 3.6% solution in 5-ml ampoule (180 mg of active compound).	
6.5.5.2 American trypanosom	iasis	
honen: Janala	Tablet: 12.5 mg; 100 mg.	
benznidazole	Tablet (scored): 50 mg.	
nifurtimox	Tablet: 30 mg; 120 mg; 250 mg.	
7. ANTIMIGRAINE MEDICIN	NES	
7.1 For treatment of acute att	ack	
ibuprofen Tablet: 200 mg; 400 mg.		
naracatamal	Oral liquid: 125 mg/5 ml.	
paracetamol	Tablet: 300 mg to 500 mg.	
7.2 For prophylaxis	·	
propranolol	Tablet: 20 mg; 40 mg (hydrochloride).	
8. ANTINEOPLASTICS AND	IMMUNOSUPPRESSIVES	
8.1 Immunosuppressive medi	cines	
Complementary List		
	Powder for injection: 100 mg (as sodium salt) in vial.	
azathioprine	Tablet (scored): 50 mg.	
	Capsule: 25 mg.	
ciclosporin	Concentrate for injection: 50 mg/ml in 1-ml ampoule for organ transplantation.	

8.2 Cytotoxic and adjuvant medicines

Medicines listed below should be used according to protocols for treatment of the diseases.

Compleme	ntary 1	List
----------	---------	------

ACUTE	LYMPHOBL	ASTIC I	FUKAFMIA

STEP 1		
asparaginase	Powder for injection: 10 000 IU in vial.	
dexamethasone	Oral liquid: 2 mg/5 ml.	
mercaptopurine	Tablet: 50 mg.	
methotrexate	Powder for injection: 50 mg (as sodium salt) in vial.	
methotrexute	Tablet: 2.5 mg (as sodium salt).	
	Injection: 40 mg/ml (as sodium succinate) in 1-ml single dose vial	
methylprednisolone	5-ml multidose vials; 80 mg/ml (as sodium succinate) in 1-ml singl dose vial.	
prednisolone	Oral liquid: 5 mg/ml.	
vincristine	Powder for injection: 1 mg; 5 mg (sulfate) in vial.	
STEP 2		
cyclophosphamide	Powder for injection: 500 mg in vial.	
cytarabine	Powder for injection: 100 mg in vial.	
daunorubicin	Powder for injection: 50 mg (hydrochloride) in vial.	
doxorubicin	Powder for injection: 10 mg; 50 mg (hydrochloride) in vial.	
hydrocortisone	Powder for injection: 100 mg (as sodium succinate) in vial.	
methotrexate	Powder for injection: 50 mg (as sodium salt) in vial.	
thioguanine	Solid oral dosage form: 40 mg.	

WILMS' TUMOUR (NEPHROBLASTOMA)

STEP 1 & STEP 2	
dactinomycin	Powder for injection: 500 micrograms in vial.
daunorubicin	Powder for injection: 50 mg (hydrochloride) in vial.
vincristine	Powder for injection: 1 mg; 5 mg (sulfate) in vial.

BURKITT'S LYMPHOMA

Powder for injection: 500 mg in vial.
Powder for injection: 100 mg in vial.
Powder for injection: 10 mg; 50 mg (hydrochloride) in vial.
Oral liquid: 5 mg/ml.
Powder for injection: 1 mg; 5 mg (sulfate) in vial.

ADJUVANT MEDICINES	
allopurinol	Tablet: 100 mg; 300 mg.
	Injection: 100 mg/ml in 4-ml and 10-ml ampoules.
mesna	Tablet: 400 mg; 600 mg.
8.3 Hormones and antiho	rmones
9. ANTIPARKINSONISN	/ MEDICINES
10. MEDICINES AFFECT	TING THE BLOOD
10.1 Antianaemia medicii	nes
<i>C</i> 11	Oral liquid: equivalent to 25 mg iron (as sulfate)/ml.
ferrous salt	Tablet: equivalent to 60 mg iron.
folic acid	Tablet: 1 mg; 5 mg.
hydroxocobalamin	Injection: 1 mg (as acetate, hydrochloride or as sulfate) in 1-ml ampoule.
10.2 Medicines affecting	coagulation
	Injection: 1 mg/ml; 10 mg/ml in 5-ml ampoule.
phytomenadione	Tablet: 10 mg.
Complementary List	<u>'</u>
heparin sodium	Injection: 1000 IU/ml; 5000 IU/ml in 1-ml ampoule.
protamine sulfate	Injection: 10 mg/ml in 5-ml ampoule.
□ warfarin	Tablet: 0.5 mg; 1 mg; 2 mg; 5 mg (sodium salt).
10.3 Other medicines for	haemoglobinopathies
Complementary list	
deferoxamine*	Powder for injection: 500 mg (mesilate) in vial. * Deferasirox oral form may be an alternative, depending on cost and availability.
hydroxycarbamide	Solid oral dosage form: 200 mg; 500 mg; 1 g.
	AND PLASMA SUBSTITUTES (under construction, the section at will be published together with the full report of the Expert Committee
12. CARDIOVASCULAR	MEDICINES
12.1 Antianginal medicin	es
12.2 Antiarrhythmic med	icines
12.3 Antihypertensive me	edicines
□ enalapril	Tablet: 2.5 mg; 5 mg (as hydrogen maleate).
12.4 Medicines used in he	eart failure
	Injection: 250 micrograms/ml in 2-ml ampoule.
digoxin	Oral liquid: 50 micrograms/ml.

	Tablet: 62.5 micrograms; 250 micrograms.
	Injection: 10 mg/ml in 2-ml ampoule.
furosemide	Oral liquid: 20 mg/5 ml.
	Tablet: 40 mg.
Complementary List	
dopamine	Injection: 40 mg (hydrochloride) in 5-ml vial.
12.5 Antithrombotic medi	cines
12.6 Lipid-lowering agent	s R
13. DERMATOLOGICAL	MEDICINES (topical)
13.1 Antifungal medicines	
□ miconazole	Cream or ointment: 2% (nitrate).
terbinafine	Cream: 1% or Ointment: 1% terbinafine hydrochloride.
13.2 Anti-infective medici	nes
	Cream (as mupirocin calcium): 2%.
mupirocin	Ointment: 2%.
potassium permanganate	Aqueous solution: 1:10 000.
л ки П	Cream: 1%.
silver sulfadiazine a	a >2 months.
13.3 Anti-inflammatory ar	nd antipruritic medicines
D hotomothecom o	Cream or ointment: 0.1% (as valerate).
□ betamethasone a	a Hydrocortisone preferred in neonates.
calamine	Lotion.
hydrocortisone	Cream or ointment: 1% (acetate).
13.4 Medicines affecting s	kin differentiation and proliferation
benzoyl peroxide	Cream or lotion: 5%.
coal tar	Solution: 5%.
□ podophyllum resin	Solution: 10% to 25%.
salicylic acid	Solution: 5%.
urea	Cream or ointment: 5%; 10%.
13.5 Scabicides and pedic	ulicides
D hongyl hongoete	Lotion: 25%.
□ benzyl benzoate a	a >2 years.
permethrin	Cream: 5%.
bermennn	Lotion: 1%.
14. DIAGNOSTIC AGEN	rs

14.1 Ophthalmic medicines	
fluorescein	Eye drops: 1% (sodium salt).
□ tropicamide	Eye drops: 0.5%.
14.2 Radiocontrast media	
Complementary List	
barium sulfate	Aqueous suspension.
15. DISINFECTANTS AND AN	TISEPTICS
15.1 Antiseptics	
□ chlorhexidine	Solution: 5% (digluconate).
□ ethanol	Solution: 70% (denatured).
□ polyvidone iodine	Solution: 10% (equivalent to 1% available iodine).
15.2 Disinfectants	
☐ chlorine base compound	Powder: (0.1% available chlorine) for solution.
□ chloroxylenol	Solution: 4.8%.
glutaral	Solution: 2%.
16. DIURETICS	
	Injection: 10 mg/ml in 2-ml ampoule.
furosemide	Oral liquid: 20 mg/5 ml.
	Tablet: 10 mg; 20 mg; 40 mg.
Complementary List	
□ hydrochlorothiazide	Tablet (scored): 25 mg.
mannitol	Injectable solution: 10%; 20%.
spironolactone	Oral liquid: 5 mg/5 ml; 10 mg/5 ml; 25 mg/5 ml.
cpinemeterie	Tablet: 25 mg.
17. GASTROINTESTINAL MED	DICINES
Complementary List	
□ pancreatic enzymes	Age-appropriate formulations and doses including lipase, protease and amylase.
17.1 Antiulcer medicines	
D omonrogolo	Powder for oral liquid: 20 mg; 40 mg sachets.
□ omeprazole	Solid oral dosage form: 10 mg; 20 mg; 40 mg.
	Injection: 25 mg/ml (as hydrochloride) in 2-ml ampoule.
□ ranitidine	Oral liquid: 75 mg/5 ml (as hydrochloride).
	Tablet: 150 mg (as hydrochloride).
17.2 Antiemetic medicines	

	Injection: 4 mg/ml in 1-ml amp salt).	ooule (as disodium phosphate
dexamethasone	Oral liquid: 0.5 mg/5 ml; 2 mg/5	/5 ml.
	Solid oral dosage form: 0.5 mg	;; 0.75 mg; 1.5 mg; 4 mg.
metoclopramide a	Injection: 5 mg (hydrochloride)/ml in 2-ml ampoule.
	Oral liquid: 5 mg/5 ml.	
	Tablet: 10 mg (hydrochloride).	
	a Not in neonates.	
	Injection: 2 mg base/ml in 2-m	l ampoule (as hydrochloride).
	Oral liquid: 4 mg base/5 ml.	
ondansetron a	Solid oral dosage form: Eq 4 m	ng base; Eq 8 mg base.
	a >1 month.	
17.3 Anti-inflammatory medicia	1 03	
17.4 Laxatives R		
17.5 Medicines used in diarrhoo	ea	
17.5.1 Oral rehydration		
	Powder for dilution in 200 ml;	500 ml; 1 L.
	glucose:	75 mEq
	sodium:	75 mEq or mmol/L
	chloride:	65 mEq or mmol/L
	potassium: citrate:	20 mEq or mmol/L 10 mmol/L
	osmolarity:	245 mOsm/L
oral rehydration salts	glucose:	13.5 g/L
	sodium chloride:	2.6 g/L
	potassium chloride:	1.5 g/L
	trisodium citrate dihydrate+:	2.9 g/L
		_
	+ trisodium citrate dihydrate may	5 g/L. However, as the stability of this
	latter formulation is very poor unc	•
	recommended when manufactured	-
17.5.2 Medicines for diarrhoea	in children	
	Solid oral dosage form: 20 mg.	[c].
zinc sulfate*		e should be used as an adjunct to
40 HODMONES OTHER END	oral rehydration salts.	D CONTRACERTIVES
18. HORMONES, OTHER END		D CONTRACEPITVES
18.1 Adrenal hormones and syr		\ \
fludrocortisone	Tablet: 100 micrograms (acetat	e).
hydrocortisone	Tablet: 5 mg; 10 mg; 20 mg.	
18.2 Androgens		
18.3 Contraceptives		

18.3.1 Oral hormonal contrace	otives
18.3.2 Injectable hormonal cor	traceptives
18.3.3 Intrauterine devices	
18.3.4 Barrier methods	
18.3.5 Implantable contracepti	ves
18.4 Estrogens	
18.5 Insulins and other medicing	nes used for diabetes
glucagon	Injection: 1 mg/ml.
insulin injection (soluble)	Injection: 100 IU/ml in 10-ml vial.
intermediate-acting insulin	Injection: 100 IU/ml in 10-ml vial (as compound insulin zinc suspension or isophane insulin).
Complementary List	
metformin	Tablet: 500 mg (hydrochloride).
18.6 Ovulation inducers	
18.7 Progestogens	
18.8 Thyroid hormones and ant	ithyroid medicines
levothyroxine	Tablet: 25 micrograms; 50 micrograms; 100 micrograms (sodium salt).
Complementary List	
Lugol's solution	Oral liquid: about 130 mg total iodine/ml.
potassium iodide	Tablet: 60 mg.
propylthiouracil	Tablet: 50 mg.
19. IMMUNOLOGICALS	
19.1 Diagnostic agents	
All tuberculins should comply with the	WHO Requirements for Tuberculins.
tuberculin, purified protein derivative (PPD)	Injection.
19.2 Sera and immunoglobuling	3
All plasma fractions should comply wit	h the WHO Requirements
antirabies immunoglobulin (human)	Injection: 150 IU/ml in vial.
antitetanus immunoglobulin (human)	Injection: 500 IU in vial.
antivenom immunoglobulin*	Injection.
anavenom miniunogiobumi	* Exact type to be defined locally.
diphtheria antitoxin	Injection: 10 000 IU; 20 000 IU in vial.
19.3 Vaccines	
	st will need to be determined by each country after consideration emiology and national priorities. The list below details the

vaccines for which there is either a recommendation from the Strategic Advisory Group of Experts on Immunization (SAGE) (http://www.who.int/immunization/sage_conclusions/en/index.html) and/or a WHO position paper (http://www.who.int/immunization/documents/positionpapers/en/index.html). This site will be updated as new position papers are published and contains the most recent information and recommendations.

All vaccines should comply with the WHO Requirements for Biological Substances.

WHO noted the need for vaccines used i	n children to be polyvalent.
BCG vaccine	
cholera vaccine	
diphtheria vaccine	
Haemophilus influenzae type b vaccine	
hepatitis A vaccine	
hepatitis B vaccine	
influenza vaccine	
Japanese encephalitis vaccine	
measles vaccine	
meningococcal meningitis vaccine	
mumps vaccine	
pertussis vaccine	
pneumococcal vaccine	
poliomyelitis vaccine	
rabies vaccine	
rotavirus vaccine	
rubella vaccine	
tetanus vaccine	
typhoid vaccine	
varicella vaccine	
yellow fever vaccine	
20. MUSCLE RELAXANTS (PER INHIBITORS	RIPHERALLY-ACTING) AND CHOLINESTERASE
neostigmine	Injection: 500 micrograms in 1-ml ampoule; 2.5 mg (metilsulfate) in 1-ml ampoule.
	Tablet: 15 mg (bromide).
suxamethonium	Injection: 50 mg (chloride)/ml in 2-ml ampoule.
Susumentonum	Powder for injection: (chloride), in vial.
□ vecuronium	Powder for injection: 10 mg (bromide) in vial.

Complementary List

	Injection: 1 mg in 1-ml ampoule.
pyridostigmine	Tablet: 60 mg (bromide).
21. OPHTHALMOLOGICAL PR	
21.1 Anti-infective agents	
aciclovir	Ointment: 3% W/W.
azithromycin	Solution (eye drops): 1.5%
gentamicin	Solution (eye drops): 0.3% (sulfate).
□ ofloxacin	Solution (eye drops): 0.3%.
□ tetracycline	Eye ointment: 1% (hydrochloride).
21.2 Anti-inflammatory agents	, ,
□ prednisolone	Solution (eye drops): 0.5% (sodium phosphate).
21.3 Local anaesthetics	(-)
_	Solution (eye drops): 0.5% (hydrochloride).
□ tetracaine a	Not in preterm neonates.
21.4 Miotics and antiglaucoma	
21.5 Mydriatics	
	Solution (eye drops): 0.1%; 0.5%; 1% (sulfate).
atropine* a	* Or homatropine (hydrobromide) or cyclopentolate (hydrochloride).
	a >3 months.
Complementary List	
epinephrine (adrenaline)	Solution (eye drops): 2% (as hydrochloride).
21.6 Anti-vascular endothelial g	rowth factor (VEGF)
22. OXYTOCICS AND ANTIOX	YTOCICS
22.1 Oxytocics	
22.2 Antioxytocics (tocolytics)	
23. PERITONEAL DIALYSIS S	OLUTION
Complementary List	
intraperitoneal dialysis solution (of appropriate composition)	Parenteral solution.
24. MEDICINES FOR MENTAL	AND BEHAVIOURAL DISORDERS
24.1 Medicines used in psychoti	c disorders
Complementary List	
	Injection: 25 mg (hydrochloride)/ml in 2-ml ampoule.
chlorpromazine	Oral liquid: 25 mg (hydrochloride)/5 ml.
	Tablet: 10 mg; 25 mg; 50 mg; 100 mg (hydrochloride).

	Injection: 5 mg in 1-ml ampoule.
haloperidol	Oral liquid: 2 mg/ml.
	Solid oral dosage form: 0.5 mg; 2 mg; 5 mg.
24.2 Medicines used in mood	disorders
24.2.1 Medicines used in dep	ressive disorders
Complementary List	
a 🗆	Solid oral dosage form: 20 mg (as hydrochloride).
fluoxetine a	a >8 years.
24.2.2 Medicines used in bipo	olar disorders R
24.3 Medicines for anxiety di	sorders R
24.4 Medicines used for obse	essive compulsive disorders R
24.5 Medicines for disorders	due to psychoactive substance use R
25. MEDICINES ACTING O	N THE RESPIRATORY TRACT
25.1 Antiasthmatic medicines	
	Inhalation (aerosol): 100 micrograms per dose; 200 micrograms
□ budesonide	per dose.
epinephrine (adrenaline)	Injection: 1 mg (as hydrochloride or hydrogen tartrate) in 1-ml ampoule.
	Injection: 50 micrograms (as sulfate)/ml in 5-ml ampoule.
□ salbutamol	Metered dose inhaler (aerosol): 100 micrograms (as sulfate) per dose.
	Respirator solution for use in nebulizers: 5 mg (as sulfate)/ml.
26. SOLUTIONS CORRECTI DISTURBANCES	NG WATER, ELECTROLYTE AND ACID-BASE
26.1 Oral	
oral rehydration salts	See section 17.5.1.
potassium chloride	Powder for solution.
26.2 Parenteral	
glucose	Injectable solution: 5% (isotonic); 10% (hypertonic); 50% (hypertonic).
glucose with sodium chloride	Injectable solution: 5% glucose, 0.9% sodium chloride (equivalent to 150 mmol/L Na+ and 150 mmol/L Cl-); 5% glucose, 0.45% sodium chloride (equivalent to 75 mmol/L Na+ and 75 mmol/L Cl-).
potassium chloride	Solution for dilution: 7.5% (equivalent to K 1 mmol/ml and Cl 1 mmol/ml); 15% (equivalent to K 2 mmol/ml and Cl 2 mmol/ml).
sodium chloride	Injectable solution: 0.9% isotonic (equivalent to Na+ 154 mmol/L, Cl-154 mmol/L).

sodium hydrogen carbonate	Injectable solution: 1.4% isotonic (equivalent to Na+167 mmol/L, HCO ₃ -167 mmol/L). Solution: 8.4% in 10-ml ampoule (equivalent to Na+1000 mmol/L, HCO ₃ -1000 mmol/L).	
□ sodium lactate, compound solution	Injectable solution.	
26.3 Miscellaneous		
water for injection	2-ml; 5-ml; 10-ml ampoules.	
27. VITAMINS AND MINERALS		
ascorbic acid	Tablet: 50 mg.	

	Oral liquid: 400 IU/ml.
cholecalciferol*	Solid oral dosage form: 400 IU; 1000 IU.
	* Ergocalciferol can be used as an alternative.
	Capsule: 200 mg.
iodine	Iodized oil: 1 ml (480 mg iodine); 0.5 ml (240 mg iodine) in ampoule (oral or injectable); 0.57 ml (308 mg iodine) in dispenser bottle.
pyridoxine	Tablet: 25 mg (hydrochloride).
	Capsule: 100 000 IU; 200 000 IU (as palmitate).
	Oral oily solution: 100 000 IU (as palmitate)/ml in multidose dispenser.
retinol	Tablet (sugar-coated): 10 000 IU (as palmitate).
	Water-miscible injection: 100 000 IU (as palmitate) in 2-ml ampoule.
riboflavin	Tablet: 5 mg.
sodium fluoride	In any appropriate topical formulation.
thiamine	Tablet: 50 mg (hydrochloride).
Complementary List	
calcium gluconate	Injection: 100 mg/ml in 10-ml ampoule.
28. EAR, NOSE AND TH	ROAT MEDICINES IN CHILDREN
acetic acid	Topical: 2%, in alcohol.
□ budesonide	Nasal spray: 100 micrograms per dose.
□ ciprofloxacin	Topical: 0.3% drops (as hydrochloride).
	Nasal spray: 0.05%.
□ xylometazoline a	a Not in children less than 3 months.
29. SPECIFIC MEDICIN	ES FOR NEONATAL CARE
29.1 Medicines administe	red to the neonate

caffeine citrate	Injection: 20 mg/ml (equivalent to 10 mg caffeine base/ml).
	Oral liquid: 20 mg/ml (equivalent to 10 mg caffeine base/ml).
chlorhexidine	Solution or gel: 7.1% (digluconate) delivering 4% chlorhexidine (for umbilical cord care).
Complementary List	
□ ibuprofen	Solution for injection: 5 mg/ml.
	Solution for injection:
□ prostaglandin E	Prostaglandin E 1: 0.5 mg/ml in alcohol. Prostaglandin E 2: 1 mg/ml.
surfactant	Suspension for intratracheal instillation: 25 mg/ml or 80 mg/ml.
29.2 Medicines administered	d to the mother
30. MEDICINES FOR DISE	ASES OF JOINTS
30.1 Medicines used to trea	t gout
30.2 Disease modifying age	nts used in rheumatoid disorders (DMARDs)
Complementary List	
hydroxychloroquine	Solid oral dosage form: 200 mg (as sulfate).
methotrexate	Tablet: 2.5 mg (as sodium salt).
30.3 Juvenile joint diseases	
	Suppository: 50 mg to 150 mg.
acetylsalicylic acid* (acute or chronic use)	Tablet: 100 mg to 500 mg.
	* For use for rheumatic fever, juvenile arthritis, Kawasaki

Table 1: Medicines with age and weight restrictions

atazanavir	>25 kg
atropine	>3 months
benzyl benzoate	>2 years
betamethasone topical preparations	Hydrocortisone preferred in neonates
cefazolin	>1 month
ceftriaxone	>41 weeks corrected gestational age
diloxanide	>25 kg
doxycycline	>8 years (except for serious infections e.g. cholera)
efavirenz	>3 years or >10 kg
emtricitabine	>3 months
fluoxetine	>8 years
ibuprofen	>3 months (except IV form for patent ductus arteriosus)
mefloquine	>5 kg or >3 months
metoclopramide	Not in neonates
ondansetron	>1 month
saquinavir	>25 kg
silver sulfadiazine	>2 months
tetracaine	Not in preterm neonates
trimethoprim	>6 months
xylometazoline	>3 months

Annex 1: Explanation of dosage forms

A. Principal dosage forms used in EMLc - Oral administration

Term	Definition
Solid oral dosage form	Refers to tablets or capsules or other solid dosage forms such as 'melts' that are immediate-release preparations. It implies that there is no difference in clinical efficacy or safety between the available dosage forms, and countries should therefore choose the form(s) to be listed depending on quality and availability.
	The term 'solid oral dosage form' is <i>never</i> intended to allow any type of modified-release tablet.
	Refers to:
	uncoated or coated (film-coated or sugar-coated) tablets that are intended to be swallowed whole; 1
Tablet	 unscored and scored*; tablets that are intended to be chewed before being swallowed; tablets that are intended to be dispersed or dissolved in water or another suitable liquid before being swallowed; tablets that are intended to be crushed before being swallowed.
	The term 'tablet' without qualification is <i>never</i> intended to allow any type of modified-release tablet.
	Refers to a specific type of tablet: chewable - tablets that are intended to be chewed before being swallowed;
	dispersible - tablets that are intended to be dispersed in water or another suitable liquid before being swallowed;
	soluble - tablets that are intended to be dissolved in water or another
Tablet (qualified)	suitable liquid before being swallowed; crushable - tablets that are intended to be crushed before being swallowed;
	scored - tablets bearing a break mark or marks where sub-division is intended in order to provide doses of less than one tablet;
	sublingual - tablets that are intended to be placed beneath the tongue.
	The term 'tablet' is <i>always</i> qualified with an additional term (in parentheses) in entries where one of the following types of tablet is intended: gastro-resistant (such tablets may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.

^{*} Scored tablets may be divided for ease of swallowing, provided dose is a whole number of tablets.

Term	Definition
	Refers to hard or soft capsules.
Capsule	The term 'capsule' without qualification is <i>never</i> intended to allow any type of modified-release capsule.
Capsule (qualified)	The term 'capsule' with qualification refers to gastro-resistant (such capsules may sometimes be described as enteric-coated or as delayed-release), prolonged-release or another modified-release form.
Granules	Preparations that are issued to patient as granules to be swallowed without further preparation, to be chewed, or to be taken in or with water or another suitable liquid. The term 'granules' without further qualification is <i>never</i> intended to allow any type of modified-release granules.
Oral powder	Preparations that are issued to patient as powder (usually as single-dose) to be taken in or with water or another suitable liquid.
Oral liquid	Liquid preparations intended to be <i>swallowed</i> i.e. oral solutions, suspensions, emulsions and oral drops, including those constituted from powders or granules, but <i>not</i> those preparations intended for <i>oromucosal administration</i> e.g. gargles and mouthwashes. Oral liquids presented as powders or granules may offer benefits in the form of better stability and lower transport costs. If more than one type of oral liquid is available on the same market (e.g. solution, suspension, granules for reconstitution), they may be interchanged and in such cases should be bioequivalent. It is preferable that oral liquids do not contain sugar and that solutions for children do not contain alcohol.

B. Principal dosage forms used in EMLc - Parenteral administration

Term	Definition
Injection	Refers to solutions, suspensions and emulsions including those
	constituted from powders or concentrated solutions.
Injection (qualified)	Route of administration is indicated in parentheses where relevant.
Injection (oily)	The term injection is qualified by (oily) in relevant entries.
Intravenous infusion	Refers to solutions and emulsions including those constituted from
	powders or concentrated solutions.

C. Other dosage forms

Mode of	Term to be used	
administration		
To the eye	Eye drops, eye ointments.	
Topical	For liquids: lotions, paints.	
	For semi-solids: cream, ointment.	
Rectal	Suppositories, gel or solution.	
Vaginal	Pessaries or vaginal tablets.	
Inhalation	Powder for inhalation, pressurized inhalation, nebulizer.	

INDEX

abacavir (ABC)		chloroquine	
acetic acid	28	chloroxylenol	
acetylcysteine		chlorpromazine	
acetylsalicylic acid	29	cholecalciferol	28
aciclovir	.12, 25	cholera vaccine	24
albendazole	8	ciclosporin	17
allopurinol	19	ciprofloxacin	10, 28
amikacin	12	clindamycin	11
amitriptyline	6	clofazimine	11
amodiaquine	15	cloxacillin	9
amoxicillin	9	coagulation factor IX	20
amoxicillin + clavulanic acid	9	coagulation factor VIII	20
amphotericin B	.12, 15	coal tar	21
ampicillin	9	cyclizine	6
antirabies immunoglobulin (human)		cyclophosphamide	18
antitetanus immunoglobulin (human)		cycloserine	
antivenom immunoglobulin		cytarabine	
artemether		dactinomycin	
artemether + lumefantrine		dapsone	
artesunate	15	daunorubicin	
artesunate + amodiaquine	15	deferoxamine	
artesunate + mefloquine		dexamethasone	
ascorbic acid		dextran 70	
asparaginase		diazepam	
atazanavir		didanosine (ddI)	
atropine		diethylcarbamazine	
azathioprine		digoxin	
azithromycin		diloxanide	
barium sulfate		dimercaprol	
BCG vaccine		diphtheria antitoxin	
benzathine benzylpenicillin		diphtheria vaccine	
benznidazole		docusate sodium	
benzoyl peroxide		dopamine	
benzyl benzoate		doxorubicin	
benzylpenicillin		doxycycline	
betamethasone		efavirenz (EFV or EFZ)	·
budesonide	.27. 28	eflornithine	
bupivacaine	•	emtricitabine (FTC)	
caffeine citrate		enalapril	
calamine		epinephrine (adrenaline)	
calcium gluconate		erythromycin	
capreomycin		ethambutol	
carbamazepine		ethanol	
cefalexin		ethionamide	
cefazolin		ethosuximide	
cefotaxime		ferrous salt	
ceftazidime		fluconazole	
ceftriaxone		flucytosine	
charcoal, activated		fludrocortisone	
chloramphenicol		fluorescein	
chlorhexidine		fluoxetine	
chlorine base compound		folic acid	•
	· · · · · · · · · · · · · · · · · · ·		

fomepizole	7	melarsoprol	17
fresh frozen plasma	19	meningococcal meningitis vaccine	25
furosemide	20, 22	mercaptopurine	18
gentamicin	10, 25	mesna	19
glucagon	23	metformin	24
glucose	27	methotrexate	18, 29
glucose with sodium chloride	27	methylprednisolone	18
glutaral	22	metoclopramide	22
griseofulvin	12	metronidazole	
Haemophilus influenzae type b vaccin	e24	miconazole	20
haloperidol	26	midazolam	6
halothane		miltefosine	15
heparin sodium	19	morphine	5, 6
hepatitis A vaccine	24	mumps vaccine	25
hepatitis B vaccine		mupirocin	
human normal immunoglobulin		naloxone	
hydrochlorothiazide		neostigmine	25
hydrocortisone	7, 18, 21, 23	nevirapine (NVP)	13
hydroxocobalamin		niclosamide	
hydroxycarbamide		nifurtimox	
hydroxychloroquine		nitrofurantoin	
hyoscine hydrobromide		nitrous oxide	
ibuprofen		nystatin	12
imipenem + cilastatin		ofloxacin	
influenza vaccine		omeprazole	
insulin injection (soluble)		ondansetron	
intermediate-acting insulin		oral rehydration salts	
intraperitoneal dialysis solution		oseltamivir	
iodine		oxamniquine	
isoflurane	5	oxygen	
isoniazid		p-aminosalicylic acid	
ivermectin	8	pancreatic enzymes	
Japanese encephalitis vaccine		paracetamol	
kanamycin		paromomycin	
ketamine		pentamidine	
lactulose	6	permethrin	21
lamivudine (3TC)	13	pertussis vaccine	
lamivudine + nevirapine + stavudin		phenobarbital	
lamivudine + nevirapine + zidovudi		phenoxymethylpenicillin	
lamivudine + zidovudine		phenytoin	
levamisole	8	phytomenadione	
levofloxacin	12	platelet concentrates	
levothyroxine		pneumococcal vaccine	
lidocaine		podophyllum resin	
lidocaine + epinephrine (adrenaline)5	poliomyelitis vaccine	
lopinavir + ritonavir (LPV/r)		polyvidone iodine	
loratadine		potassium chloride	
lorazepam	8	potassium iodide	
Lugol's solution		potassium permanganate	
mannitol		praziquantel	
measles vaccine	25	prednisolone	
mebendazole	8	primaquine	
mefloquine	16	procaine benzylpenicillin	
meglumine antimoniate		proguanil	

propofol5	stavudine (d4T)	13
propranolol17	streptomycinstreptomycin	12
propylthiouracil24	succimer	7
prostaglandin E28	sulfadiazine	16
protamine sulfate19	sulfadoxine + pyrimethamine	16
pyrantel8	sulfamethoxazole + trimethoprim	11, 16
pyrazinamide11	suramin sodium	17
pyridostigmine25	surfactant	28
pyridoxine28	suxamethonium	25
pyrimethamine16	terbinafine	21
quinine16	tetanus vaccine	25
rabies vaccine25	tetracaine	26
ranitidine22	tetracycline	25
red blood cells19	thiamine	28
retinol28	thioguanine	18
ribavirin14	triclabendazole	8
riboflavin28	trimethoprim	11
rifampicin11	tropicamide	21
ritonavir14	tuberculin, purified protein derivative	
rotavirus vaccine25	typhoid vaccine	25
rubella vaccine25	urea	21
salbutamol27	valproic acid (sodium valproate)	8
salicylic acid21	vancomycin	11
saquinavir (SQV)14	varicella vaccine	25
senna7	vecuronium	25
silver sulfadiazine21	vincristine	18
sodium calcium edetate7	warfarin	19
sodium chloride27	water for injection	27
sodium fluoride28	whole blood	19
sodium hydrogen carbonate27	xylometazoline	28
sodium lactate, compound solution27	yellow fever vaccine	25
sodium stibogluconate15	zidovudine (ZDV or AZT)	13
spironolactone22	zinc sulfate	23